LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

LLY

764

+2.13%↑

JNJ

176.45

-0.55%↓

ABBV

216.08

-0.77%↓

UNH

339.82

-2.33%↓

AZN

77.61

-0.58%↓

Search

Ionis Pharmaceuticals Inc

Cerrado

SectorSalud

61.27 0.28

Resumen

Variación precio

24h

Actual

Mínimo

60.58

Máximo

61.52

Métricas clave

By Trading Economics

Ingresos

270M

124M

Ventas

320M

452M

Margen de beneficio

27.331

Empleados

1,069

EBITDA

294M

150M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

+12.19% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

3.2B

9.7B

Apertura anterior

60.99

Cierre anterior

61.27

Noticias sobre sentimiento de mercado

By Acuity

13%

87%

21 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Neutral Evidence

Ionis Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

16 sept 2025, 17:03 UTC

Principales Movimientos del Mercado

BrainsWay Shares Rise on FDA Clearance of Major Depressive Disorder Treatment

16 sept 2025, 16:49 UTC

Principales Movimientos del Mercado
Adquisiciones, fusiones, absorciones

GD Culture Shares Drop After Deal for Pallas Capital

16 sept 2025, 16:11 UTC

Principales Movimientos del Mercado

Corbus Shares Rise on FDA Fast-Track Designation for Cancer Drug

16 sept 2025, 23:40 UTC

Charlas de Mercado

Nikkei May Decline as Yen Strengthens -- Market Talk

16 sept 2025, 23:34 UTC

Charlas de Mercado

Gold Edges Higher Ahead of FOMC Decision -- Market Talk

16 sept 2025, 23:20 UTC

Charlas de Mercado

Restaurant Brands NZ Can Outperform When Cycle Turns -- Market Talk

16 sept 2025, 21:10 UTC

Adquisiciones, fusiones, absorciones

U.S. Investors, Trump Close In on TikTok Deal With China -- WSJ

16 sept 2025, 20:51 UTC

Charlas de Mercado

U.S. Home Sales, New Home Listings Fall in August -- Market Talk

16 sept 2025, 20:50 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

16 sept 2025, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Basic Materials Roundup: Market Talk

16 sept 2025, 20:25 UTC

Ganancias

The AI Trade Has Stocks Near Highs Again. Some Tech Names Remain on the Sidelines -- Barrons.com

16 sept 2025, 20:24 UTC

Ganancias

These Stocks Moved the Most Today: Oracle, Tesla, Alphabet, Dave & Buster's, Chipotle, and More -- Barrons.com

16 sept 2025, 19:19 UTC

Charlas de Mercado

U.S. Natural Gas Futures Extend Winning Streak -- Market Talk

16 sept 2025, 18:52 UTC

Charlas de Mercado

Oil Futures Advance on Russia Concerns, Weak Dollar -- Market Talk

16 sept 2025, 18:44 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

16 sept 2025, 18:44 UTC

Charlas de Mercado

EssilorLuxottica Well-Positioned in Growing Smart-Glasses Market -- Market Talk

16 sept 2025, 18:40 UTC

Adquisiciones, fusiones, absorciones

Details Emerge on U.S.-China TikTok Deal -- WSJ

16 sept 2025, 18:38 UTC

Charlas de Mercado

Meta Seen With Long-Term Opportunity to Lead in Smart Glasses -- Market Talk

16 sept 2025, 18:19 UTC

Charlas de Mercado

Gold Settles at New High Ahead of Fed Decision -- Market Talk

16 sept 2025, 18:01 UTC

Charlas de Mercado

U.S. Dollar Weakness Supports Oil's Gains -- Market Talk

16 sept 2025, 17:34 UTC

Charlas de Mercado

Any Question the Bank of Canada Will Cut Now Look to Have Vanished -- Market Talk

16 sept 2025, 16:53 UTC

Ganancias

Software Companies Are Fighting Back With AI. The Stocks Are Still Hurting. -- Barrons.com

16 sept 2025, 16:20 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Basic Materials Roundup: Market Talk

16 sept 2025, 16:15 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Global Commodities Roundup: Market Talk

16 sept 2025, 16:09 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Global Energy Roundup: Market Talk

16 sept 2025, 16:09 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Canada Industry Minister to Meet Mining CEOs on Merger -- Market Talk

16 sept 2025, 15:35 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

16 sept 2025, 15:35 UTC

Charlas de Mercado

Gold Soars Past $3,700 Ahead of Fed Decision -- Market Talk

16 sept 2025, 15:22 UTC

Charlas de Mercado

More Investors Think Dollar is Overvalued in Latest BofA Survey -- Market Talk

16 sept 2025, 15:21 UTC

Charlas de Mercado

Sterling Considered Most Overvalued in Nearly 10 Years -- Market Talk

Comparación entre iguales

Cambio de precio

Ionis Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

12.19% repunte

Estimación a 12 meses

Media 68.55 USD  12.19%

Máximo 96 USD

Mínimo 43 USD

De acuerdo con 21 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Ionis Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

21 ratings

16

Comprar

4

Mantener

1

Vender

Puntuación técnica

By Trading Central

29.78 / 33.645Soporte y Resistencia

Corto Plazo

Neutral Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

21 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Ionis Pharmaceuticals Inc

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.
help-icon Live chat